Skip to content

Author

A. Ghanem

We have 2 of 8 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Anthracycline-free versus anthracycline-based neoadjuvant therapy in HER2-positive breast cancer: A Propensity score-matched real-world study.

BACKGROUND Anthracycline-free TCHP and anthracycline-based AC-THP are both used as neoadjuvant dual anti-HER2 regimens for HER2-positive breast cancer, but direct comparisons accounting for HER2 immunohistochemistry (IHC) intensity are lacking. Because IHC 3+ tumors respond substantially better to dual blockade, any be...

B. Sharaf, F. Tamimi, Mohammad Alzoubi et al. · 0 citations
Open access Oct 2026

Treatment Outcomes of Patients with Early-Stage Breast Cancer Meeting NATALEE Eligibility Criteria. A Real-World Cohort Study

The findings provide real-world historical outcome data for patients who would now be considered candidates for adjuvant ribociclib and may serve as a benchmark for evaluating outcomes following adoption of adjuvant ribociclib.

H. Abdel-Razeq, M. Horani, F. Tamimi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.